Product Images Pregabalin

This is a medication package of Pregabalin 150mg (NDC 71205-396-60) containing 60 capsules made by ScieGen Pharmaceuticals, Inc. The capsules are hard gelatin and filled with white to off white powder. Each capsule is imprinted with "SG" on the cap and "354" on the body with black ink. The lot number is 00000 and the expiration date is 00/00/00. The medication guide should be provided to each patient. It is for prescription use only. Store at 25°C (77°F) and keep out of reach of children.*

The text is a mixture of numbers and characters that do not form a coherent description. Therefore, the description is not available.*

This text likely represents data related to different medications and their impact on patient pain relief. It includes various doses of "Pregatalin" and "Pregabalin", along with a measure of improvement in pain from a baseline level. The first line appears to show the percentage of patients who experienced improvement, while subsequent lines indicate different dosage amounts and frequencies. The last line likely shows a time measurement or duration of the study.*

The text appears to be a table or a graph with medication dosages and their corresponding effects. It also mentions "statistically significant vs. placebo." Without further context, it is difficult to provide a specific description.*

The text shows a graph that compares the percentage of improvement in pain from baseline for patients taking Pregabalin at daily doses of 300mg and 450mg, as well as for patients taking a placebo. The horizontal axis measures improvement in pain from baseline, while the vertical axis shows the percentage of patients. The graph shows a significant increase in pain relief for patients taking Pregabalin compared to those taking a placebo, with a higher percentage of patients experiencing improvement at the 450mg dose compared to the 300mg dose.*

This appears to be a table that shows the percentage of subjects without LTR (not clear what LTR stands for) for a drug called "Progabain" and a placebo over a period of 120 days. The percentages range from 0% to 100%.*

The text is describing a chart or graph showing the percentage of subjects who have improved from "Bassin to ek 12 BOCF". There is no actual data provided and it is not clear what "Bassin" or "ek" refer to.*

This appears to be a formula used for calculating creatinine clearance, a measure of kidney function. The formula involves subtracting the patient's age from 140 and multiplying the result by their weight in kilograms, then multiplying that by a correction factor of 0.85 for female patients. The result is then multiplied by their serum creatinine level in milligrams per deciliter, and divided by 72 to obtain their estimated creatinine clearance in milliliters per minute.*